Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy?

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 4, 2003, Pages 278-281

  Kaiser, Thomas ^a,b   Florack, Christiane ^a   Stephan, Uta ^a   Sawicki, Peter T ^a,b  

^a DleM Inst for Evidence Based Med   (Germany)

^b St Franziskus Hospital Koln   (Germany)

Author keywords

Albuminuria; Blood pressure; Diabetic nephropathy; Glomerular filtration rate; Hypertension; Normotension

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; ENALAPRIL; NISOLDIPINE; PLACEBO; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEDICAL LITERATURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; URINE LEVEL; VALIDATION PROCESS;

EID: 0042878583     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030040801     Document Type: Article

References (22)

1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
3. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-42.
4. Bauer JH, Reams GP, Hewett J et al. A randomised, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992;20:443-57.
5. Elving LD, Wetzels JMF, van Lier HJJ, de Nobel E, Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994;37:604-09.
6. Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994;3:292-300.
7. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997;46:481-7.
8. Sawicki PT. Stabilisation of glomerular filtration rate over two years in patients with diabetic nephropathy and intensified therapy regimes. Nephrol Dial Transplant 1997;12:1890-9.
9. Hovind P, Rossing F, Tarnow L, Smith UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001;59:702-09.
10. Rossing F, Hougaard P, Parving HH. Risk factors for development of incipient and overt nephropathy in Type 1 diabetic patients. Diabetes Care 2002;25:859-64.
11. American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2002;25(Suppl 1):S85-S89.
12. SIGN. Management of diabetic nephropathy. http://www.sign.ac.uk/guidelines/fulltext/55/section5.html (accessed 13 February 2003).
13. Ramsay LE, Williams B, Johnston GD et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.
14. Sawicki PT, Berger M. Measuring progression of diabetic nephropathy Review. Eur J Clin Invest 1994;24:651-5.
15. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.6 [updated January 2003]. http://www.cochrane.de/cochrane/handbook/handbook.htm (accessed 13 February 2003).
16. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
17. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive BP control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
18. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of BP control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64.
19. Lewis JB, Berl T, Bain RP, Rohde RP, Lewis EJ. Effect of intensive BP control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999;34:809-17.
20. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34.
21. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9.
22. Parving HH, Hommel E, Damkjaer Nielsen M, Giese J. Effect of captopril on BP and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989;299:533-6.